Skip to content

Study · Animal study (in vivo) · mouse · 2023

15 results

Abaloparatide Has the Same Catabolic Effects on Bones of Mice When Infused as PTH (1-34).

Le Henaff C, Finnie B, Pacheco M, He Z, Johnson J, Partridge NC

JBMR plus5 Jan 2023

PMID36751417 (opens in a new tab)PMCIDPMC9893269 (opens in a new tab)DOI10.1002/jbm4.10710 (opens in a new tab)PepBankPUB-36751417
Download PDFPubMedAsk about this study
Jump to 15 results

Summary

Abaloparatide is a peptide analog of parathyroid hormone-related protein (PTHrP 1-34) and was approved in 2017 as the second osteoanabolic peptide for treating osteoporosis. We previously showed that intermittent abaloparatide is equally as effective as PTH (1-34). This study was designed to compare the catabolic effects of PTH (1-34) and abaloparatide on bone in young female wild-type mice. Two-month-old C57Bl/6J female mice were continuously infused with human PTH (1-34) or abaloparatide at 80 μg/kg BW/day or vehicle for 2 weeks. At euthanasia, DEXA-PIXImus was performed to assess bone mineral density (BMD) in the whole body, femurs, tibiae, and vertebrae. Bone turnover marker levels were measured in sera, femurs were harvested for micro-computer tomography (μCT) analyses and histomorphometry, and tibiae were separated into cortical and trabecular fractions for gene expression analyses. Our results demonstrated that the infusion of abaloparatide resulted in a similar decrease in BMD as infused PTH (1-34) at all sites. μCT and histomorphometry analyses showed similar decreases in cortical bone thickness and BMD associated with an increase in bone turnover from the increased bone formation rate found by in vivo double labeling and serum P1NP and increased bone resorption as shown by osteoclast numbers and serum cross-linked C-telopeptide. Trabecular bone did not show major changes with either treatment. Osteoblastic gene expression analyses of trabecular and cortical bone revealed that infusion of PTH (1-34) or abaloparatide led to similar and different actions in genes of osteoblast differentiation and activity. As with intermittent and in vitro treatment, both infused PTH (1-34) and abaloparatide similarly regulated downstream genes of the PTHR1/SIK/HDAC4 pathway such as Sost and Mmp13 but differed for those of the PTHR1/SIK/CRTC pathway. Taken together, at the same dose, infused abaloparatide causes the same high bone turnover as infused PTH (1-34) with a net resorption in female wild-type mice. © 2023 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study15

15 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, infused abaloparatide decreased whole-body BMD similarly to infused PTH (1-34).

    In plain wordsIn mice, infused abaloparatide reduced whole-body bone density similarly to infused PTH.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeWhole-body BMD
    Study

    mousen: not reported in source

    Young female wild-type C57Bl/6J mice
    Comparator
    PTH (1-34)
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg/kg BW/day · continuous infusion · 2 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Our results demonstrated that the infusion of abaloparatide resulted in a similar decrease in BMD as infused PTH (1-34) at all sites.
    2 context sentences
    Summary · context
    At euthanasia, DEXA-PIXImus was performed to assess bone mineral density (BMD) in the whole body, femurs, tibiae, and vertebrae.
    Summary · context
    Two-month-old C57Bl/6J female mice were continuously infused with human PTH (1-34) or abaloparatide at 80 μg/kg BW/day or vehicle for 2 weeks.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, infused abaloparatide decreased femoral BMD similarly to infused PTH (1-34).

    In plain wordsIn mice, infused abaloparatide reduced femur bone density similarly to infused PTH.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeFemoral BMD
    Study

    mousen: not reported in source

    Young female wild-type C57Bl/6J mice
    Comparator
    PTH (1-34)
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg/kg BW/day · continuous infusion · 2 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Our results demonstrated that the infusion of abaloparatide resulted in a similar decrease in BMD as infused PTH (1-34) at all sites.
    2 context sentences
    Summary · context
    At euthanasia, DEXA-PIXImus was performed to assess bone mineral density (BMD) in the whole body, femurs, tibiae, and vertebrae.
    Summary · context
    Two-month-old C57Bl/6J female mice were continuously infused with human PTH (1-34) or abaloparatide at 80 μg/kg BW/day or vehicle for 2 weeks.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, infused abaloparatide decreased tibial BMD similarly to infused PTH (1-34).

    In plain wordsIn mice, infused abaloparatide reduced tibia bone density similarly to infused PTH.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeTibial BMD
    Study

    mousen: not reported in source

    Young female wild-type C57Bl/6J mice
    Comparator
    PTH (1-34)
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg/kg BW/day · continuous infusion · 2 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Our results demonstrated that the infusion of abaloparatide resulted in a similar decrease in BMD as infused PTH (1-34) at all sites.
    2 context sentences
    Summary · context
    At euthanasia, DEXA-PIXImus was performed to assess bone mineral density (BMD) in the whole body, femurs, tibiae, and vertebrae.
    Summary · context
    Two-month-old C57Bl/6J female mice were continuously infused with human PTH (1-34) or abaloparatide at 80 μg/kg BW/day or vehicle for 2 weeks.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, infused abaloparatide decreased vertebral BMD similarly to infused PTH (1-34).

    In plain wordsIn mice, infused abaloparatide reduced vertebral bone density similarly to infused PTH.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeVertebral BMD
    Study

    mousen: not reported in source

    Young female wild-type C57Bl/6J mice
    Comparator
    PTH (1-34)
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg/kg BW/day · continuous infusion · 2 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Our results demonstrated that the infusion of abaloparatide resulted in a similar decrease in BMD as infused PTH (1-34) at all sites.
    2 context sentences
    Summary · context
    At euthanasia, DEXA-PIXImus was performed to assess bone mineral density (BMD) in the whole body, femurs, tibiae, and vertebrae.
    Summary · context
    Two-month-old C57Bl/6J female mice were continuously infused with human PTH (1-34) or abaloparatide at 80 μg/kg BW/day or vehicle for 2 weeks.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, infused abaloparatide decreased cortical thickness similarly to PTH (1-34).

    In plain wordsIn mice, infused abaloparatide reduced cortical bone thickness similarly to PTH.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeCortical thickness
    Study

    mousen: not reported in source

    Young female wild-type C57Bl/6J mice
    Comparator
    PTH (1-34)
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg/kg BW/day · continuous infusion · 2 weeksAs given in this study (mouse).

    Source sentences

    Summary
    μCT and histomorphometry analyses showed similar decreases in cortical bone thickness and BMD associated with an increase in bone turnover
    1 context sentence
    Summary · context
    Two-month-old C57Bl/6J female mice were continuously infused with human PTH (1-34) or abaloparatide at 80 μg/kg BW/day or vehicle for 2 weeks.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, infused abaloparatide decreased cortical BMD similarly to PTH (1-34).

    In plain wordsIn mice, infused abaloparatide reduced cortical bone density similarly to PTH.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeCortical BMD
    Study

    mousen: not reported in source

    Young female wild-type C57Bl/6J mice
    Comparator
    PTH (1-34)
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg/kg BW/day · continuous infusion · 2 weeksAs given in this study (mouse).

    Source sentences

    Summary
    μCT and histomorphometry analyses showed similar decreases in cortical bone thickness and BMD associated with an increase in bone turnover
    1 context sentence
    Summary · context
    Two-month-old C57Bl/6J female mice were continuously infused with human PTH (1-34) or abaloparatide at 80 μg/kg BW/day or vehicle for 2 weeks.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, infused abaloparatide increased bone turnover similarly to PTH (1-34).

    In plain wordsIn mice, infused abaloparatide increased bone turnover similarly to PTH.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeBone turnover
    Study

    mousen: not reported in source

    Young female wild-type C57Bl/6J mice
    Comparator
    PTH (1-34)
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg/kg BW/day · continuous infusion · 2 weeksAs given in this study (mouse).

    Source sentences

    Summary
    μCT and histomorphometry analyses showed similar decreases in cortical bone thickness and BMD associated with an increase in bone turnover
    1 context sentence
    Summary · context
    Two-month-old C57Bl/6J female mice were continuously infused with human PTH (1-34) or abaloparatide at 80 μg/kg BW/day or vehicle for 2 weeks.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, abaloparatide infusion increased bone formation rate.

    In plain wordsIn mice, abaloparatide infusion increased bone formation rate.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseBone formation rate
    Study

    mousen: not reported in source

    Young female wild-type C57Bl/6J mice
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg/kg BW/day · continuous infusion · 2 weeksAs given in this study (mouse).

    Source sentences

    Summary
    from the increased bone formation rate found by in vivo double labeling and serum P1NP and increased bone resorption as shown by osteoclast numbers and serum cross-linked C-telopeptide.
    1 context sentence
    Summary · context
    Two-month-old C57Bl/6J female mice were continuously infused with human PTH (1-34) or abaloparatide at 80 μg/kg BW/day or vehicle for 2 weeks.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, abaloparatide infusion increased serum P1NP.

    In plain wordsIn mice, abaloparatide infusion increased the bone formation marker P1NP.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseSerum P1NP
    Study

    mousen: not reported in source

    Young female wild-type C57Bl/6J mice
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg/kg BW/day · continuous infusion · 2 weeksAs given in this study (mouse).

    Source sentences

    Summary
    from the increased bone formation rate found by in vivo double labeling and serum P1NP and increased bone resorption as shown by osteoclast numbers and serum cross-linked C-telopeptide.
    1 context sentence
    Summary · context
    Two-month-old C57Bl/6J female mice were continuously infused with human PTH (1-34) or abaloparatide at 80 μg/kg BW/day or vehicle for 2 weeks.
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, abaloparatide infusion increased osteoclast numbers.

    In plain wordsIn mice, abaloparatide infusion increased bone-resorbing cell numbers.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseOsteoclast numbers
    Study

    mousen: not reported in source

    Young female wild-type C57Bl/6J mice
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg/kg BW/day · continuous infusion · 2 weeksAs given in this study (mouse).

    Source sentences

    Summary
    from the increased bone formation rate found by in vivo double labeling and serum P1NP and increased bone resorption as shown by osteoclast numbers and serum cross-linked C-telopeptide.
    1 context sentence
    Summary · context
    Two-month-old C57Bl/6J female mice were continuously infused with human PTH (1-34) or abaloparatide at 80 μg/kg BW/day or vehicle for 2 weeks.
  11. 11AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, abaloparatide infusion increased serum cross-linked C-telopeptide.

    In plain wordsIn mice, abaloparatide infusion increased a blood marker of bone resorption.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseSerum cross-linked C-telopeptide
    Study

    mousen: not reported in source

    Young female wild-type C57Bl/6J mice
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg/kg BW/day · continuous infusion · 2 weeksAs given in this study (mouse).

    Source sentences

    Summary
    from the increased bone formation rate found by in vivo double labeling and serum P1NP and increased bone resorption as shown by osteoclast numbers and serum cross-linked C-telopeptide.
    1 context sentence
    Summary · context
    Two-month-old C57Bl/6J female mice were continuously infused with human PTH (1-34) or abaloparatide at 80 μg/kg BW/day or vehicle for 2 weeks.
  12. 12AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, neither abaloparatide nor PTH (1-34) produced major trabecular bone changes.

    In plain wordsIn mice, neither abaloparatide nor PTH produced major trabecular bone changes.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeTrabecular bone
    Study

    mousen: not reported in source

    Young female wild-type C57Bl/6J mice
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg/kg BW/day · continuous infusion · 2 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Trabecular bone did not show major changes with either treatment.
    1 context sentence
    Summary · context
    Two-month-old C57Bl/6J female mice were continuously infused with human PTH (1-34) or abaloparatide at 80 μg/kg BW/day or vehicle for 2 weeks.
  13. 13AnimalAnimal study (in vivo)Mechanism

    In female mice, abaloparatide and PTH (1-34) had similar and different effects on osteoblast differentiation and activity genes.

    In plain wordsIn mice, abaloparatide and PTH shared some effects on bone-forming cell genes but differed in others.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    MixedOsteoblastic gene expression
    Study

    mousen: not reported in source

    Young female wild-type C57Bl/6J mice
    Comparator
    PTH (1-34)
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg/kg BW/day · continuous infusion · 2 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Osteoblastic gene expression analyses of trabecular and cortical bone revealed that infusion of PTH (1-34) or abaloparatide led to similar and different actions in genes of osteoblast differentiation and activity.
    1 context sentence
    Summary · context
    Two-month-old C57Bl/6J female mice were continuously infused with human PTH (1-34) or abaloparatide at 80 μg/kg BW/day or vehicle for 2 weeks.
  14. 14AnimalAnimal study (in vivo)Mechanism

    In female mice, infused abaloparatide and PTH (1-34) similarly regulated PTHR1/SIK/HDAC4 downstream genes, including Sost and Mmp13.

    In plain wordsIn mice, infused abaloparatide and PTH similarly regulated genes downstream of the PTHR1/SIK/HDAC4 pathway.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    Direction not reportedPTHR1/SIK/HDAC4 downstream genes
    Study

    mousen: not reported in source

    Young female wild-type C57Bl/6J mice
    Comparator
    PTH (1-34)
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg/kg BW/day · continuous infusion · 2 weeksAs given in this study (mouse).

    Source sentences

    Summary
    As with intermittent and in vitro treatment, both infused PTH (1-34) and abaloparatide similarly regulated downstream genes of the PTHR1/SIK/HDAC4 pathway such as Sost and Mmp13 but differed for those of the PTHR1/SIK/CRTC pathway.
    1 context sentence
    Summary · context
    Two-month-old C57Bl/6J female mice were continuously infused with human PTH (1-34) or abaloparatide at 80 μg/kg BW/day or vehicle for 2 weeks.
  15. 15AnimalAnimal study (in vivo)Mechanism

    In female mice, infused abaloparatide and PTH (1-34) differed in their regulation of PTHR1/SIK/CRTC downstream genes.

    In plain wordsIn mice, infused abaloparatide and PTH differed in their effects on genes downstream of the PTHR1/SIK/CRTC pathway.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    Direction not reportedPTHR1/SIK/CRTC downstream genes
    Study

    mousen: not reported in source

    Young female wild-type C57Bl/6J mice
    Comparator
    PTH (1-34)
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg/kg BW/day · continuous infusion · 2 weeksAs given in this study (mouse).

    Source sentences

    Summary
    As with intermittent and in vitro treatment, both infused PTH (1-34) and abaloparatide similarly regulated downstream genes of the PTHR1/SIK/HDAC4 pathway such as Sost and Mmp13 but differed for those of the PTHR1/SIK/CRTC pathway.
    1 context sentence
    Summary · context
    Two-month-old C57Bl/6J female mice were continuously infused with human PTH (1-34) or abaloparatide at 80 μg/kg BW/day or vehicle for 2 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.